| Literature DB >> 28217866 |
Kanza M Khan1, Adam D Collier1,2, Darya A Meshalkina2,3, Elana V Kysil3, Sergey L Khatsko4, Tatyana Kolesnikova4, Yury Yu Morzherin4, Jason E Warnick2,5, Allan V Kalueff2,3,4,6, David J Echevarria1,2.
Abstract
Despite the high prevalence of neuropsychiatric disorders, their aetiology and molecular mechanisms remain poorly understood. The zebrafish (Danio rerio) is increasingly utilized as a powerful animal model in neuropharmacology research and in vivo drug screening. Collectively, this makes zebrafish a useful tool for drug discovery and the identification of disordered molecular pathways. Here, we discuss zebrafish models of selected human neuropsychiatric disorders and drug-induced phenotypes. As well as covering a broad range of brain disorders (from anxiety and psychoses to neurodegeneration), we also summarize recent developments in zebrafish genetics and small molecule screening, which markedly enhance the disease modelling and the discovery of novel drug targets.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28217866 PMCID: PMC5466539 DOI: 10.1111/bph.13754
Source DB: PubMed Journal: Br J Pharmacol ISSN: 0007-1188 Impact factor: 8.739